eNewsletter - Education and Research

Faculty Awards (October 2014)

Investigator Research Sponsor
Chandra Belani A Randomized, Double-blind Phase 2 Study of Ruxolitinib or Placebo in Combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of  Subjects with NSCLC that is Stage IIIB with Pleural/Pericardial Effusion, Stage IV or Recurrent Incyte Corp.
Chandra Belani Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced of Metastatic Squamous NSCLC AbbVie Inc.
Chandra Belani A Randomized Phase 2, Double-blind, Placebo-controlled, Multicenter Study Comparing Pemetrexed in Combination with TH-302 vs. Pemetrexed in Combination with Placebo as Second-line Chemotherapy for Advanced NSCLC Threshold Pharmaceuticals, Inc.
W. Christopher Ehmann A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma Millennium Pharmaceuticals
Craig Meyers Effect of HPV16 and ART on the Epigenome Leading to AIDS-Associated Oral Cancer NIH
Arun Sharma Chemoprevention of Metastatic Colorectal Cancer University of Louisville (NIH sub-award)
Jianxun Song Directed Differentiation of HBV-specific CTL from iPSC for Cell-based Therapies NIH
Cristina Truica A Phase 2, 2-Stage, 2-Cohort Study of BMN673 Administered to Germline BRCA Mutation Subjects with Locally Advance and/or Metastatic Breast Cancer BioMarin Pharmaceutical Inc.
Cristina Truica A Multicenter, Multinational, Phase II Study to Evaluate Drug A in Combination with Drug B and Standard Neoadjuvant Anthracycline-based Chemotherapy in Patients F. Hoffmann-La Roche Ltd

Faculty Publications (August  - October 2014)

  1. Borland, M.G., Krishnan, P., Lee, C., Albrecht, P.P., Shan, W., Bility, M.T., Marcus, C.B., Lin, J.M., Amin, S., Gonzalez, F.J., Perdew, G.H., and Peters, J.M.  2014. Modulation of Aryl Hydrocarbon Receptor (AHR)-dependent Signaling by Peroxisome Proliferator-activated Receptor ß/d (PPARß/d) in Keratinocytes. Carcinogenesis 35(7):1602-12.
  2. Chakraborty, S.A., Kazi, A.A., Khan, T.M., and Grigoryev, S.A.  2014. Nucleosome-Positioning Sequence Repeats Impact Chromatin Silencing in Yeast Minichromosomes. Genetics. Epub ahead of print.
  3. Heipertz, E.L., Davies, M.L., Lin, E., and Norbury, C.C. 2014.  Prolonged Antigen Presentation following an Acute Virus Infection Requires Direct and Then Cross-Presentation.  J Immunol 193(8):4169-77.
  4. Hu, J., Budgeon, L.R., Balogh, K.K., Peng, X., Cladel, N.M., and Christensen, N.D.  2014.  Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits. Trials Vaccinol 3:134-142.
  5. Lee, S.Y., Slagle-Webb, B., Rizk, E., Patel, A., Miller, P.A., Sung, S.S., Connor, J.R.  2014.  Characterization of a novel anti-cancer compound for astrocytomas. PLoS One9(9):e108166
  6. Menvielle, G., Truong, T., Jellouli, F., Stücker, I., Brenner, H., Field, J.K., Hosgood, H.D., Lan, Q., Landi, M.T., Hung, R.J., Lazarus, P., McLaughlin, J., Morgenstern, H., Muscat, J.E., Ruano-Ravina, A., Schwartz, A.G., Seow, A., Spitz, M.R., Tardon, A., Zhang, Z.F., and Luce, D. 2014. Education and Lung Cancer Among Never Smokers. Epidemiology 25(6):934-5.
  7. Plano, D., Amin, S. and Sharma, A.K. 2014.  Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors.  J Med Chem 57(13):5509-24.
  8. Ryndock, E.J. and Meyers, C. 2014.  A risk for non-sexual transmission of human papillomavirus? Expert Rev Anti Infect Ther 12(10):1165-70.
  9. Sinha, R., Cooper, T.K., Rogers, C.J., Sinha, I., Turbitt, W.J., Calcagnotto, A., Perrone, C.E., and Richie, J.P. Jr.  2014.  Dietary methionine restriction inhibits prostatic intraepithelial neoplasia in TRAMP mice.  Prostate.  Epub ahead of print.
  10. Tursiella, M.L., Bowman, E.R., Wanzeck, K.C., Throm, R.E., Liao, J., Zhu, J., and Sample, C.E. 2014.  Epstein-Barr Virus Nuclear Antigen 3A Promotes Cellular Proliferation by Repression of the Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1. PLoS Pathog 10(10):e1004415.